You just read:

Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma

News provided by

Infinity Pharmaceuticals, Inc.

Jun 14, 2016, 05:45 ET